SCHEMBL6753936

SCHEMBL6753936

CO[C@H]([C@H](O)[C@@H](O)C=O)[C@@H](C)O

nearest known ligand 0.30

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.30
MAPT P10636 1/20 0.30
CYP2C9 P11712 1/20 0.30
CYP2C19 P33261 1/20 0.30
HSD17B10 Q99714 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7151280 1.00 CYP3A4 (0.30) CYP3A4MAPTCYP2C9CYP2C19HSD17B10
SCHEMBL8528774 1.00 CYP3A4 (0.30) CYP3A4MAPTCYP2C9CYP2C19HSD17B10
SCHEMBL5457345 1.00 CYP3A4 (0.30) CYP3A4MAPTCYP2C9CYP2C19HSD17B10
SCHEMBL29944830 0.84
SCHEMBL22748759 0.84
SCHEMBL182612 0.84
SCHEMBL7151615 0.84
SCHEMBL30437675 0.84
SCHEMBL7147900 0.84
SCHEMBL29389821 0.84

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11312986-B2 Biosynthesis of everninomicin analogs in Micromonospora carbonacea var aurantiaca VANDERBILT UNIVERSITY (US) 2022-04-26 US disclosed
EP-3387133-B1 BIOSYNTHESIS OF EVERNINOMICIN ANALOGS IN MICROMONOSPORA CARBONACEA VAR AURANTIACA UNIV VANDERBILT (US) 2021-11-17 EP disclosed
US-20200392553-A1 BIOSYNTHESIS OF EVERNINOMICIN ANALOGS IN MICROMONOSPORA CARBONACEA VAR AURANTIACA VANDERBILT UNIVERSITY 2020-12-17 US disclosed
US-10696996-B2 Biosynthesis of everninomicin analogs in Micromonospora carbonacea var aurantiaca VANDERBILT UNIVERISTY (US) 2020-06-30 US disclosed
US-20190093141-A1 BIOSYNTHESIS OF EVERNINOMICIN ANALOGS IN MICROMONOSPORA CARBONACEA VAR AURANTIACA VANDERBILT UNIVERSITY 2019-03-28 US disclosed
EP-3387133-A1 BIOSYNTHESIS OF EVERNINOMICIN ANALOGS IN MICROMONOSPORA CARBONACEA VAR AURANTIACA Vanderbilt University (US) 2018-10-17 EP disclosed
WO-2017100650-A1 BIOSYNTHESIS OF EVERNINOMICIN ANALOGS IN MICROMONOSPORA CARBONACEA VAR AURANTIACA VANDERBILT UNIVERSITY (US) 2017-06-15 WO disclosed
US-20040006026-A1 Avilamycin derivatives COMBINATURE BIOPHARM AG (DE) 2004-01-08 US disclosed
US-6562514-B1 Stabilized vanadium electrolyte solutions for all-vanadium redox cells and batteries PINNACLE VRB LIMITED (AU) 2003-05-13 US disclosed
US-6468688-B2 CHARGING, DISCHARGING EFFICIENCY; VANADIUM ELECTROLYTE PINNACLE VRB LIMITED (AU) 2002-10-22 US disclosed
US-20010028977-A1 Charging, discharging efficiency; vanadium electrolyte JD HOLDING INC. (KY) 2001-10-11 US disclosed
US-6143443-A ALL-VANADIUM REDOX BATTERY, COMPRISING THE STABILIZED ELECTROLYTE PINNACLE ARB LIMITED (AU) 2000-11-07 US disclosed
EP-0829104-A1 HIGH ENERGY DENSITY VANADIUM ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND ALL-VANADIUM REDOX CELLS AND BATTERIES CONTAINING HIGH ENERGY VANADIUM ELECTROLYTE SOLUTIONS UNISEARCH LIMITED (AU) 1998-03-18 EP disclosed
EP-0729648-A4 STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS UNISEARCH LTD (AU) 1997-01-02 EP disclosed
EP-0729648-A1 STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS UNISEARCH LIMITED (AU) 1996-09-04 EP disclosed
WO-1995012219-A1 STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS UNISEARCH LIMITED (AU) 1995-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040006026-A1 Avilamycin derivatives AMPD3, AMPD2, ADA CYP3A4 682/4885MAPT 3599/4885CYP2C9 1907/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.